Navigation Links
Xceed Molecular Names Fran Tuttle to Its Board of Trustees

WELLESLEY, Mass., Oct. 9 /PRNewswire/ -- Xceed Molecular Corporation, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced today that Fran Tuttle has been appointed to Xceed's board of directors. Ms. Tuttle is president and chief executive officer of HX Diagnostics, a California-based company focused on developing a point-of-care diagnostic for avian flu.

"Fran is the ideal complement to our board," said Xceed's President and CEO, David Deems. "She has more than 20 years of leadership in the diagnostics industry -- including significant experience with commercialization of novel technologies. Her knowledge, counsel, and close connections with thought leaders in the field will be invaluable to us as we continue to further develop our products and solutions for multiplexed gene-expression tests for clinical research today, and in vitro diagnostics tomorrow."

Prior to HX Diagnostics, Ms. Tuttle was president and chief executive officer of Protedyne Corporation (now part of LabCorp), which developed robotics for the molecular-diagnostic-testing industry. Previously, she was senior vice president of near patient testing at Bayer Diagnostics, one of the world's largest diagnostic companies. At Bayer, she was responsible for a worldwide business of $400 million. Before joining Bayer Diagnostics, she spent 20 years at Chiron Diagnostics (formerly Ciba Corning Diagnostics), a leader in molecular and immunodiagnostics. Ms. Tuttle began her career as a CPA at Peat, Marwick, Mitchell and Company (now KPMG). She holds a master's in business administration from Harvard Business School as well as bachelor's degrees in accounting from the University of North Carolina at Chapel Hill and German from Duke University.

About Xceed Molecular

Xceed's vision is to advance molecular diagnostics and improve health outcomes by providing a cost-effective, automated system and services that facilitate the rapid translation of novel multiplexed genomic tests from research into routine clinical use. We designed our proprietary system to perform multiplexed molecular assays with superior accuracy, reproducibility, speed, and scalability at significantly lower cost than conventional array- or PCR-based systems. Our offerings include: the Ziplex(TM) System for automated gene-expression analysis, comprising an automated workstation, TipChip consumable arrays, and reagents (available in the US and Canada for research use only); Signature Chips -- pre-configured arrays focusing on a number of specific disease targets; and custom array services. Xceed's R&D and manufacturing operations are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit

SOURCE Xceed Molecular Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AIDS toll set to exceed Black Death
2. America’s Demand For Organic Foods Far Exceeds the Suppl
3. Mercury Levels In Canned Tuna Exceed Guidelines
4. Cholesterol in Stroke Patients Exceeds National Guidelines
5. Dengue Deaths in Cambodia This Year Exceed 2006 Toll
6. Molecular markers for early diagnosis of breast and ovarian cancer
7. Scientists Developed Map For Brain Molecular Communities
8. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
9. Molecular Flaw Detected in Aggressive Breast Cancers
10. Molecular Computer Developed To perform Calculations From Within Human Body
11. Lung cancer molecular profile discovered by researchers.
Post Your Comments:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: